New Weight-Loss pill VCT220 enters final testing phase
NCT ID NCT06939296
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether VCT220, a daily pill that targets GLP-1 receptors, can help overweight or obese adults lose weight. About 840 participants will take either a high dose, low dose, or placebo for 12 months. The main goals are to see how much weight they lose and how many lose at least 5% of their body weight.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VCT220 (a GLP-1 receptor agonist pill)
What this could lead to
If successful, this could offer a new daily pill to help people with obesity or overweight lose weight and improve related health issues like prediabetes or high blood pressure.
What could go wrong
This is a phase 3 trial, but results are not yet public. The drug may cause side effects, and weight loss may vary. It is not a cure for obesity, and long-term use may be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital （ There are multiple sites in this clinical trial）
Beijing, Beijing Municipality, China